A Chinese scientist reviewing laboratory equipment

Research news

This section contains news items that were not issued as a press release.

Thursday, 13 November 2014
AstraZeneca and Isis Pharmaceuticals to co-develop targeted oligonucleotide delivery methods AstraZeneca and Isis Pharmaceuticals Inc. today announced a strategic alliance to discover and develop novel delivery methods for antisense oligonucleotides. The new delivery approaches seek to target the desired tissue more effectively.
Tuesday, 23 September 2014
MedImmune receives fast track designation from FDA for development of MEDI3902  for prevention of nosocomial pneumonia AstraZeneca announced today that its global biologics research and development arm, MedImmune, has received fast track designation from the US Food and Drug Administration (FDA) for its investigational monoclonal antibody (mAb) MEDI3902 for the prevention of nosocomial pneumonia caused by Pseudomonas aeruginosa (P. aeruginosa)
Wednesday, 3 September 2014
AstraZeneca and Redx Pharma agree research collaboration targeting genetic drivers of tumour growth AstraZeneca today announced that it has entered into a research collaboration with Redx Pharma Limited to discover and develop new molecules targeting a genetic driver of tumour growth and survival.
Wednesday, 20 August 2014
AstraZeneca and Mitsubishi Tanabe Pharma Corporation announce research collaboration in diabetic nephropathy AstraZeneca and Mitsubishi Tanabe Pharma Corporation (MTPC) today announce a three-year research collaboration in the area of diabetic nephropathy. The aim of the research collaboration is to leverage complementary strengths, expertise and assets to validate and progress novel research targets and molecules into clinical development.
Tuesday, 22 July 2014
Seven pharma companies offer up compounds to UK researchers UK researchers will be granted access to a ‘virtual library’ of deprioritised pharmaceutical compounds through a new partnership between the Medical Research Council (MRC) and seven global drug companies, announced today by Business Secretary Vince Cable.
Tuesday, 8 July 2014
AstraZeneca and Max Planck Institute announce research agreement to create satellite chemistry unit for cardiovascular and metabolic diseases AstraZeneca today announced an agreement with the Max Planck Institute of Molecular Physiology (MPI), Germany, to establish a ‘satellite unit’ in cardiovascular and metabolic disease (CVMD), linked to AstraZeneca’s CVMD Innovative Medicines unit (iMed) in Mölndal, Sweden, to study new modalities chemistry.
Tuesday, 17 June 2014
ADDC and AstraZeneca partner to foster novel drug development among academic research community Selected academic researchers to receive access to AstraZeneca’s compound library to aid in the discovery of new medicines
Tuesday, 3 June 2014
Nobel Laureate Tim Hunt to visit China for the Nobel Prize Inspiration Initiative, in partnership with AstraZeneca Nobel Laureate Tim Hunt will give a series of lectures to students and faculty at Shanghai’s Fudan University School of Pharmacy and Chengdu’s Sichuan University West China School of Medicine. Dr. Hunt, whose pioneering research on the cell cycle has profoundly impacted many aspects of biology and medicine, is visiting China as part of the 2014 Nobel Prize Inspiration Initiative (NPII).
Thursday, 15 May 2014
AstraZeneca and Tianjin Medical University sign cardiovascular research collaboration in China SHANGHAI, CHINA –AstraZeneca today announced the signing of a research collaboration in the area of cardiovascular diseases (CVDs) with Tianjin Medical University (TMU), one of China’s leading medical and scientific institutions.
Thursday, 27 March 2014
AstraZeneca and Shenzhen University Health Science Center to collaborate on chronic kidney disease SHANGHAI, CHINA –AstraZeneca today announced a research collaboration with Shenzhen University Health Science Center.